Dermata Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY Revenue (est.)
$100Knext fiscal year
FY EPS (est.)
-$2.21next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Earnings Release | 12 Nov 2026 |
| FY 2026 Annual Earnings Release | 25 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Tome Skincare Brand Launch Progress QuarterlyTarget: Launch Foundational Treatment in mid-2026
Cash and Cash Equivalents Quarterly6.9MTarget: Maintain sufficient runway to fund operations into Q1 2027
Quarterly Net Loss Quarterly-1.8MTarget: Narrow losses through reduced R&D clinical trial expenses
Watch Items
- Direct-to-Consumer (DTC) Skincare Commercialization ExecutionTrigger: Delays in mid-2026 launch of Tome Foundational TreatmentAction: Re-evaluate marketing strategy, packaging supply chain, and VP of Marketing leadership execution.
- Going Concern and Capital RunwayTrigger: Cash reserves falling below $3.0 million without alternative fundingAction: Utilize the newly registered $100 million shelf registration statement to raise equity or debt capital.
- Regulatory Compliance under MoCRATrigger: FDA challenges regarding cosmetic vs. over-the-counter (OTC) drug claims for Tome productsAction: Consult regulatory counsel to adjust marketing claims and ensure compliance with the Modernization of Cosmetics Regulation Act.
Research as of 20 Jun 2026